Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement Firms Making Drug Claims Land On Fast Track To Notoriety At FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA is compiling an ongoing list of “online advisory letters” to identify supplement firms that fail to respond within 30 days to notices about noncompliant claims. The agency anticipates spurring an uptick in NDI notifications by publishing a draft guidance by the end of the year.


Related Content

Supplement NDI Draft Guidance Discussions Snagged On Basic Criteria
New Dietary Ingredient Notification Draft Guidance Must Be Withdrawn – CRN and CHPA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts